KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Debt (2018 - 2022)

TherapeuticsMD's Total Debt history spans 8 years, with the latest figure at $1.8 million for Q3 2022.

  • For Q3 2022, Total Debt fell 99.06% year-over-year to $1.8 million; the TTM value through Sep 2022 reached $1.8 million, down 99.06%, while the annual FY2021 figure was $188.3 million, 20.79% down from the prior year.
  • Total Debt reached $1.8 million in Q3 2022 per TXMD's latest filing, down from $90.8 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $243.8 million in Q2 2020 to a low of $1.8 million in Q3 2022.
  • Average Total Debt over 5 years is $159.9 million, with a median of $187.5 million recorded in 2021.
  • Peak YoY movement for Total Debt: surged 231.19% in 2020, then plummeted 99.06% in 2022.
  • A 5-year view of Total Debt shows it stood at $73.4 million in 2018, then surged by 165.24% to $194.6 million in 2019, then rose by 22.13% to $237.7 million in 2020, then dropped by 20.79% to $188.3 million in 2021, then crashed by 99.07% to $1.8 million in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Total Debt are $1.8 million (Q3 2022), $90.8 million (Q2 2022), and $202.9 million (Q1 2022).